Evidence map›Paper›PMID 32483755›Full record

ArticleDoklady. Biochemistry and biophysics2020

Multifunctional Complexes Based on Photoluminescent Upconversion Nanoparticles for Theranostics of the HER2-Positive Tumors.

E L Guryev, A S Smyshlyaeva, N Yu Shilyagina, S Shanwar, A B Kostyuk, A A Shulga, E V Konovalova, A V Zvyagin, S M Deyev, R V Petrov

Abstract read
PubMed Publisher
In one paragraph

Article in Doklady. Biochemistry and biophysics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.5field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Photon Upconversion in Small Molecules.Molecules (Basel, Switzerland) · 2022
    Review
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

E L GuryevLobachevsky State University of Nizhny Novgorod, 603105, Nizhny Novgorod, Russia.
A S SmyshlyaevaLobachevsky State University of Nizhny Novgorod, 603105, Nizhny Novgorod, Russia.
N Yu ShilyaginaLobachevsky State University of Nizhny Novgorod, 603105, Nizhny Novgorod, Russia.
S ShanwarLobachevsky State University of Nizhny Novgorod, 603105, Nizhny Novgorod, Russia.
A B KostyukLobachevsky State University of Nizhny Novgorod, 603105, Nizhny Novgorod, Russia.
A A ShulgaShemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, 117997, Moscow, Russia.
E V KonovalovaShemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, 117997, Moscow, Russia.
A V ZvyaginLobachevsky State University of Nizhny Novgorod, 603105, Nizhny Novgorod, Russia.
S M DeyevShemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, 117997, Moscow, Russia. biomem@mail.ru.
R V PetrovShemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, 117997, Moscow, Russia.
N. I. Lobachevsky State University of Nizhny Novgorod · RUInstitute of Bioorganic Chemistry · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Combining diagnostic and therapeutic functions in one agent is a promising strategy in the development of personalized approaches to the treatment of cancer. The opportunity to combine diagnostics and therapy appeared with the development of nanobiotechnologies and was realized in the concept of theranostics. To date, a number of promising agents based on nanomaterials capable of diagnosing, targeted therapeutic effects, and monitoring the response of tumor cells were obtained within the approach of theranostics. In this work, a new type of theranostic complexes based on upconversion nanoparticles coated with polyethylene glycol and functionalized with the DARPin-LoPE recombinant targeted toxin was developed. Selective binding of complexes to human breast adenocarcinoma cells overexpressing the HER2 receptor and specific toxicity to them were shown.

Indexed as

LuminescenceTheranostic NanomedicineAnimalsBreast NeoplasmsCHO CellsCricetinaeCricetulusErb-b2 Receptor Tyrosine KinasesFemaleHumansNanoparticlesNanostructuresPhotochemistryPolyethylene GlycolsProtein BindingThuliumERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesPolyethylene GlycolsThuliumYtterbiumHER2 receptornanoparticlestargeted therapytheranosticsupconversion nanoparticles

Identifiers

PMID32483755
OpenAlexW3032741310

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.